Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · IEX Real-Time Price · USD
28.63
+0.80 (2.87%)
Aug 8, 2022 4:00 PM EDT - Market closed
2.87%
Market Cap 1.83B
Revenue (ttm) 228.12M
Net Income (ttm) -230.22M
Shares Out 63.96M
EPS (ttm) -3.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,457,816
Open 27.67
Previous Close 27.83
Day's Range 27.22 - 29.14
52-Week Range 13.75 - 31.65
Beta 0.62
Analysts Buy
Price Target 41.14 (+43.7%)
Earnings Date Aug 4, 2022

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola a... [Read more...]

Industry Biotechnology
Employees 310
Stock Exchange NASDAQ
Ticker Symbol TVTX
Full Company Profile

Financial Performance

In 2021, TVTX's revenue was $227.49 million, an increase of 14.71% compared to the previous year's $198.32 million. Losses were -$180.09 million, 6.29% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is 41.14, which is an increase of 43.70% from the latest price.

Price Target
$41.14
(43.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -11.70% and 9.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update.

Travere Therapeutics to Report Second Quarter 2022 Financial Results

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of...

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2022, the Compensation Committee of its Board of Directors granted inducement equi...

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COVID19--Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2022, the Compensation Committee of its Board of Directors granted inducement equi...

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June ...

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase ...

Here's Why Travere Therapeutics Shares Are Rising Today

Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy. Travere Therapeutics ...

Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -41.18% and 8.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics Reports First Quarter 2022 Financial Results

Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 20...

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics to Report First Quarter 2022 Financial Results

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of t...

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

Laura Clague to step-down as CFO in August 2022 and retire in 2023

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and th...

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a no...

Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

HAYWARD, Calif.--(BUSINESS WIRE)-- #Biotech--Dr. Roy D. Baynes has been appointed Executive Vice President and Chief Medical Officer of Eikon Therapeutics effective July 11, 2022.

Other symbols: ATRANTRA

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...

Travere Prices Upsized $275 Million Convertible Senior Notes Offering

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25% conve...

Travere Announces Proposed Convertible Senior Notes Offering

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal a...

Travere Therapeutics to Present at the Barclays Global Healthcare Conference

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the Barclays Global Healthcare Conference on Thursday, Mar...

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -16.67% and 1.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Should You Buy?

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 a...